[Evaluation of efficacy, safety and tolerability rabeprazole in treatment of acid-peptic diseases ].

Background: Rabeprazole, a substituted benzimidazole, represents a new generation of proton pump inhibitors that has recently been approved by the FDA and European Union for treatment of acid-related diseases.

Objectives: To assess the efficacy and tolerability of rabeprazole 20 mg in actual conditions of use in everyday clinical practice on subjects with diagnosis of erosive gastroesophageal reflux disease and/or gastric and/or duodenal ulcer.

Patients/methods: A total of 171 outpatients (55% men, 45% women) with a mean age of 42.